• An inspirational new approach to sleep-disordered breathing

    Meeting the unmet needs of a broader population of patients

A breath of fresh air

Oventus is a Brisbane-based, medical device company established in 2012 to meet the unmet needs of Obstructive Sleep Apnoeics, nasal obstructers and non-compliant CPAP users. In 2013, Oventus worked with the CSIRO to develop a new style of custom mouthguard that has the potential to help millions of snorers and people with sleep apnoea sufferers around the world.

The result is the O2VentTM – a non-invasive sleep apnoea treatment option with a range of oral devices incorporating Oventus Airway Technology, a unique separate airway which is built into its patented design.

The O2Vent™’s unique design directs the air flow through to the back of the throat, alleviating multiple sites of obstruction including the nose, soft palate and tongue.

The device incorporates the Oventus Airway Technology, or ‘second nose’ – a unique airway built into its patented design, allowing for breathing through the device to bypass nasal resistance which can contribute to snoring and Obstructive Sleep Apnoea (OSA).

Using CAD software to create a 3D drawing of the patient’s mouth and bite, Oventus uses 3D printing technology to manufacture these custom-made medical-grade mouthguards from titanium.

Our mission

Oventus aims to become a world leader in sleep disorder treatment by commercialising our suite of revolutionary oral devices and inspiring a new paradigm of care — taking the treatment OSA to the next level by providing a real alternative for the broader population within a unique treatment platform.

Future innovation and product development

The patented airway in the O2VentTM enables exciting opportunities for dentists to offer alternative treatments to their patients. In addition to the custom oral appliance therapy range, Oventus Medical is developing a temporary device, incorporating the Oventus Airway Technology, giving dentists and patients the option to deliver immediate therapy to patients prior to progressing to a customised device.

In February 2017 Oventus Medical was announced as the lead participant in a AUD$3 Million Australian Government grant to advance research into the treatment of Obstructive Sleep Apnoea. Alongside industry and scientific experts in the field, Oventus Medical will work with NeuRA (Neuroscience Research Australia) and the CSIRO (Commonwealth Science and Industrial Research Organisation) on exciting research exploring the benefit of the Oventus airway design as a treatment approach in progressive OSA treatments such as algorithms for treatment success, in-built compliance and efficacy monitoring and miniaturised CPAP pumps.

Well advanced in the product development cycle is the ‘Oventus Connect’ – a one-size-fits-all, out-of-the-box adaptor that can potentially reduce CPAP pressure requirements and remove the need for uncomfortable masks and head straps.

As well as therapeutic advantages, the Oventus Airway Technology has the ability to facilitate diagnosis and monitoring. Currently in testing is an inbuilt form of compliance monitoring and an attachment that allows a ‘Level III’ home sleep test to be completed any time, anywhere, without wires hanging off the patient and feeding data directly to an Oventus App and online treatment monitoring portal.

About the Oventus team

The company is managed by founder and Clinical Director Dr Chris Hart BSc. BDSc.(Hons) M.Phil.(Cantab) and Chief Executive Officer Neil Anderson.

Dr Chris Hart
Clincial Director

As Clinical Director of Oventus, Dr Chris Hart is overseeing the delivery of the O2VentTM product range to patients and through clinicians.

Graduating from The University of Queensland in 1998 with a Bachelor of Dental Science with Honours and a Bachelor of Science in Biochemistry, he also studied at Cambridge University and graduated in 1999 with a Master of Philosophy in Biomedical Science.

Prior to establishing Oventus, Chris owned and managed a multi-site national dental practice, training institute and management consultancy which he sold to private equity investors. He now works full time as the Oventus Clinical Director.

Chris also acts as an adviser to various bodies within the dental industry as well as the healthcare sector more broadly on the commercial aspects of health care delivery.

Neil Anderson
Managing Director and CEO

An experienced company executive and biomaterial scientist, Neil started working with Dr Chris Hart in 2013, to develop and commercialise the O2VentTM obstructive sleep apnoea treatment and bring it to market. Neil has been responsible for managing the collaboration process with the CSIRO to develop a remotely-managed computer aided detection (CAD) imaging and 3D printing manufacturing platform, as well as the patent portfolio, quality systems and regulatory clearances for the product to date.

Neil has 30 years’ experience in commercialising medical devices and managing the process from conception to market release including applied research, developing prototypes and testing, product development, manufacturing, regulatory submissions and clinical trials.

Prior to taking on the role with Oventus, Neil founded and held the role of Chief Executive Officer of CathRx for 10 years.

In this role, Neil managed the process from the invention of the company’s technology through to commercialising a range of products leading to sales in Europe.

Neil has a Bachelor of Applied Science (Hons) and a Diploma of Management and is a Graduate of the Institute of Company Directors (GAICD).

Dan Parry
Chief Financial and Operations Officer

Dan Parry joined Oventus in December 2017 with over 20 years of experience as CFO and Company Secretary in the life science, technology and medical service sectors.

Dan has held senior finance roles with companies in the US, UK and Australia, ranging from venture-backed start-ups to NASDAQ listed companies including Astellas, Synergen, Cortech, Heska, Accera and Implicit Bioscience Ltd. His experience also includes corporate finance and internal audit roles with a Fortune 100 company and six years in public accounting where Dan qualified as a CPA in the US.

In these roles, Dan has managed finance, accounting, human resources, information technology, facilities, legal and compliance functions and mergers and acquisitions. Dan is professionally qualified as Chartered Accountant in Australia and as a CPA in the US, with an MBA from the J.L. Kellogg Graduate School of Management in Chicago.

Robin Randolph
Vice President of Marketing and Operations, North America

Starting her career as a nurse, then sleep technologist and clinical researcher, Robin Randolph is an accomplished marketing and sales executive with over 30 years’ experience in the sleep industry, including past ownership of US sleep centres.

Robin joined Oventus Medical in April 2018 as Vice President of Marketing and Operations, North America. Robin’s vast experience spans medical device commercialisation, product management, clinical education, reimbursement and sleep centre operations management.

Robin has held senior management roles in these areas for both ResMed and Fisher & Paykel Healthcare. She is passionate about education for patient management of sleep disorders, including obstructive sleep apnoea, sharing her in-depth industry knowledge and promoting the advantages of Oventus Airway Technology.